BIOPHYTIS (EPA:ALBPS) - Biophytis to Present at 15th International Pharma Licensing Symposium in Paris
Transparency directive : regulatory news
Click here to download pdf version
Biophytis to Present at 15th International Pharma Licensing Symposium in Paris
Paris (France), Cambridge (Massachusetts, United States), September 19, 2019,
7:00pm CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company focused on the development of drug candidates for the
treatment of neuromuscular diseases, announces that Stanislas Veillet, Chief
Executive Officer, will present the Company and progress with its lead drug
candidate, Sarconeos (BIO101), currently in a Phase 2b clinical trial for the
treatment of sarcopenia, a disease of ageing characterized by a loss of muscle
mass and function responsible for mobility disabilities.
The presentation will be made on Friday September 20th, 2019 at the 15th
International Pharma Licensing Symposium (IPLS) held September 18-20, 2019 in
Paris, France. Mr Veillet will also participate on the same day in a panel
discussion along with Professor Jean Mariani, Director of the Longevity
Institute, Sorbonne Université (France), who is a member of the Biophytis'
Scientific Advisory Board.
Details are as follows:
Date: Friday, September 20th, 2019
Session: D - AGEING: a New Field of Investigation & Investment
Title: New Therapeutics for Disease of Ageing
Time: 10:15am CEST
Title: The Pathology of Ageing Challenges and Opportunities
Time: 11:15am CEST
Biophytis is a clinical-stage biotechnology company focused on developing
therapeutics that slow the degenerative processes associated with aging and
improve functional outcomes for patients suffering from age-related diseases,
with a primary focus on neuromuscular diseases.
Biophytis' lead drug candidate, Sarconeos (BIO101), is an orally administered
small molecule, which is currently in a Phase 2b clinical trial for sarcopenia
(SARA-INT) in the US and Europe. Sarconeos (BIO101) is also being developed for
the treatment of Duchenne muscular dystrophy (DMD). Biophytis expects Sarconeos
(BIO101) to enter the clinic for DMD in 2020.
Biophytis is headquartered in Paris, France, and has offices in Cambridge,
Massachusetts. The Company's ordinary shares are listed on Euronext Growth
Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to securities
of Biophytis in any country. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements and estimates,
which speak only as of the date hereof. Other than as required by applicable
law, Biophytis undertakes no obligation to update or revise the information
contained in this press release. This press release has been prepared in both
French and English. In the event of any differences between the two texts, the
French language version shall prevail.
Biophytis Investor Relations Contact
Daniel Schneiderman, CFO
Tel: +1 (857) 220-9720
U.S. Media Contact
LifeSci Public Relations
Cherilyn Cecchini, M.D.
Tel: +1 (646) 876-5196
Europe Media Contact
Citigate Dewe Rogerson
Quentin Dussart / Sylvie Berrebi / Nathaniel Dahan / David Dible
Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571